AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
- Conditions
- Prefibrotic/Early Primary MyelofibrosisPolycythemia VeraEssential ThrombocythemiaJAK2 V617FHigh-risk Patients
- Interventions
- Drug: Direct Oral Anticoagulants
- Registration Number
- NCT05198960
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF). These MPNs are caused by the acquisition of mutations affecting activation/proliferation pathways in hematopoietic stem cells. The principal mutations are JAK2V617F, calreticulin (CALR exon 9) and MPL W515. ET or MFP/PreMF patients who do not carry one of these three mutations are declared as triple-negative (3NEG) cases even if they are real MPN cases.
These diseases are at high risk of thrombo-embolic complications and with high morbidity/mortality. This risk varies from 4 to 30% depending on MPN subtype and mutational status.
In terms of therapy, all patients with MPNs should also take daily low-dose aspirin (LDA) as first antithrombotic drug, which is particularly efficient to reduce arterial but not venous events.
Despite the association of a cytoreductive drug and LDA, thromboses still occur in 5-8% patients/year.
All these situations have been explored in biological or clinical assays. All of them could increase the bleeding risk. We should look at different ways to reduce the thrombotic incidence: Direct Oral Anticoagulants (DOAC)? In the general population, in medical or surgical contexts, DOACs have demonstrated their efficiency to prevent or cure most of the venous or arterial thrombotic events.
At the present time, DOAC can be used in cancer populations according to International Society on Thrombosis and Haemostasis (ISTH) recommendations, except in patients with cancer at high bleeding risk (gastro-intestinal or genito-urinary cancers). Unfortunately, in trials evaluating DOAC in cancer patients, most patients have solid rather than hematologic cancers (generally less than 10% of the patients, mostly lymphoma or myeloma).
In cancer patients, DOAC are also highly efficient to reduce the incidence of thrombosis (-30 to 60%), but patients are exposed to a higher hemorrhagic risk, especially in digestive cancer patients.
In the cancer population, pathophysiology of both thrombotic and hemorrhagic events may be quite different between solid cancers and MPN. If MPN patients are also considered to be cancer patients in many countries, the pathophysiology of thrombosis is quite specific (hyperviscosity, platelet abnormalities, clonality, specific cytokines...) and they are exposed to a lower risk of digestive hemorrhages. It is thus difficult to extend findings from the "general cancer population" to MPN patients.
Unfortunately, only scarce, retrospective data regarding the use of DOAC in MPNs are available data.
We were the first to publish a "real-life" study about the use, the impact, and the risks in this population. In this local retrospective study, 25 patients with MPN were treated with DOAC for a median time of 2.1 years. We observed only one thrombosis (4%) and three major hemorrhages (12%, after trauma or unprepared surgery). Furthermore, we have compared the benefit/risk balance compared to patients treated with LDA without difference.
With the increasing evidences of efficacy and tolerance of DOAC in large cohorts of patients including cancer patients, with their proven efficacy on prevention of both arterial and venous thrombotic events and because of the absence of prospective trial using these drugs in MPN patients, we propose to study their potential benefit as primary thrombotic prevention in MPN.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1308
-
Patients with diagnosis of PV or ET or PreMF according to WHO or BSCH criteria (bone marrow biopsy not compulsory).
-
Patients with JAK2V617F mutation (threshold allele burden > 1%).
-
Patients considered as "high-risk" patients:
- based on age (> 60-year-old)
- based on thrombotic history (compatible with antithrombotic randomization) but aged ≥ 18-year-old.
-
Length of time from MPN diagnostic to inclusion will not exceed 12 months.
- Contra-indication to aspirin or DOAC due to allergic situation or recent history of major bleeding.
- Formal indication of treatment with aspirin or DOAC (thus precluding randomization).
- Inability to give informed consent.
- Patients under curatorship/guardianship
- Concomitant use of a strong inhibitor or inducer of CYP3A4 (like ruxolitinib).
- Chronic liver disease or chronic hepatitis.
- Renal insufficiency with creatinine <30 ml/mn on Cockcroft and Gault Formula
- Patient considered at high-risk of bleeding: patients with current or recent major or clinical relevant non major bleeding gastrointestinal or cerebral bleedings
- Planned pregnancy within 24 months
- No appropriate contraception (estrogen contraception or no contraception) in women of childbearing age or breastfeeding woman
- PS>2 or life expectancy <12 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental group Direct Oral Anticoagulants Patients randomized to receive Direct Oral Anticoagulants, at the choice of the investigator Apixaban 2.5 mg both in day or Rivaroxaban 10 mg one per day, at the choice of the investigator Control group Low-dose aspirin Patients randomized to receive Low-Dose Aspirin Aspirin 100 mg one per day
- Primary Outcome Measures
Name Time Method Time to occurrence of arterial or venous thromboembolic events. Time to occurrence up to 24 months of patient follow-up Nb and type of thrombotic events during the FU
- Secondary Outcome Measures
Name Time Method Time to occurrence of major and clinically relevant non-major bleedings as defined by International Society on Thrombosis and Haemostasis Time to occurrence up to 24 months of patient follow-up Nb and type of new hemorrhagic events
Time to occurrence of arterial thromboembolic events. Time to occurrence up to 24 months of patient follow-up Nb and type of new arterial events
Time to occurrence of venous thromboembolic Time to occurrence up to 24 months of patient follow-up Nb and type of new venous events
Time to occurrence of thromboembolic and bleeding events according to the cytoreductive associated drugs Time to occurrence up to 24 months of patient follow-up Nb and type of new thromboembolic and hemorrhage events
Time to occurrence of serious adverse events others than thromboses and hemorrhages hemorrhages Time to occurrence up to 24 months of patient follow-up Nb, type and grade of adverse events observed
Overall survival and event-free survival 24 months Time to last news and time to first event
Therapeutic adherence 24 months Therapeutic adherence by Girerd auto-questionnaire
Occurrence of atrial fibrillation episode (time to occurrence). 24 months Nb and timing of atrial fibrillation event
Evaluation of Quality of life under antithrombotic drugs 24 months Evaluation of QoL by the use of EQ-5D-5L Quality of life
Evaluation of costs and incremental cost utility ratio of low-dose DOAC compared to low-dose aspirin 24 months Evaluation of benefits/costs under antithrombotic drugs
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (42)
CHU Brest
🇫🇷Brest, France
CHU Bordeaux
🇫🇷Bordeaux, France
Médipôle Hôpital Mutualiste Villeurbanne
🇫🇷Villeurbanne, France
CHU d'Angers
🇫🇷Angers, France
CH d'Annecy
🇫🇷Annecy, France
Hôpital privé Cesson-Sévigné
🇫🇷Cesson-Sévigné, France
CHU Grenoble Alpes
🇫🇷Grenoble, France
CH Libourne
🇫🇷Libourne, France
Centre Léon Bérard Lyon
🇫🇷Lyon, France
CHU de Limoges - Hôpital Dupuytren
🇫🇷Limoges, France
CHR d'Orléans
🇫🇷Orléans, France
CHU de Rennes
🇫🇷Rennes, France
Centre Henri Becquerel de Rouen
🇫🇷Rouen, France
CHU La Réunion - Site Sud
🇫🇷Saint-Pierre, France
CH d'Avignon
🇫🇷Avignon, France
CH de Béziers
🇫🇷Béziers, France
CHU de Clermont-Ferrand
🇫🇷Clermont-Ferrand, France
CHD Vendée La Roche Sur Yon
🇫🇷La Roche-sur-Yon, France
Hôpital Henri Mondor (APHP)
🇫🇷Créteil, France
CHU Le Havre
🇫🇷Le Havre, France
CH Le Mans
🇫🇷Le Mans, France
CHU de Nancy
🇫🇷Nancy, France
CHU de Nantes - Hôtel-Dieu
🇫🇷Nantes, France
Hôpital Privé du Confluent Nantes
🇫🇷Nantes, France
CH de Perpignan
🇫🇷Perpignan, France
Hôpital St-Louis (APHP)
🇫🇷Paris, France
CHIC de Quimper
🇫🇷Quimper, France
CH de Périgueux
🇫🇷Périgueux, France
CH de Rochefort
🇫🇷Rochefort, France
Clinique Sainte Anne Strasbourg
🇫🇷Strasbourg, France
CHU de Tours
🇫🇷Tours, France
CH Bretagne Atlantique Vannes
🇫🇷Vannes, France
CH de Versailles
🇫🇷Versailles, France
CH Paul-Brousse (APHP)
🇫🇷Villejuif, France
Hôpital Cochin (APHP)
🇫🇷Paris, France
CH d'Argenteuil
🇫🇷Argenteuil, France
CH de la Côte Basque Bayonne
🇫🇷Bayonne, France
CHU de Montpellier
🇫🇷Montpellier, France
CH de Morlaix
🇫🇷Morlaix, France
CH de Roubaix
🇫🇷Roubaix, France
Institut de Cancérologie Lucien Neuwirth St-Priest-en-Jarez
🇫🇷Saint-Priest-en-Jarez, France
CHU La Réunion - Site Nord Félix GUYON
🇫🇷Saint-Denis, France